Qatar's health-system order is real, but SRIT's profit is still a future test

SRIT India disclosed an international order of about QAR50 million, reported as ₹1,289.3 million, from Ooredoo QPSC for managed electronic-health and pharmacy/drug-control systems. The scope runs two years for onboarding and three years for ecosystem and rollout operations. This is a named customer order, not a market forecast, but the filing does not state cash received, billing milestones, expected margin or customer concentration after the award. [I1]

The source PDF reported a 13 November NSE market reference, not live weekend trading; that exchange-page clock could not be independently reopened for this publication. A 15 November recheck of NDTV Profit displayed ₹126.38 with a 13 November 15:30 update label, while Choice displayed ₹116.04 with a 3 November 15:51 IST update label. These are differently dated snapshots, not a same-time price contradiction or executable weekend quote. The PDF's ₹126.10–₹127.75 comparison is withdrawn as unverified. [I2][I3]

Who is it for

Adults aged 18 or older with a regulated broker and the ability to lose the whole test amount. Late teens can paper-track the milestones without buying.

What readers can do now

Build a zero-cost order-to-cash tracker. Record the contracting branch, onboarding count, invoice milestone, collection and recognised revenue. Capital: S$0. Buyer: none; this is research, not a service sale. Stop if SRIT does not disclose a first invoice or cash collection by the next two reported quarters. [I1]

Use a tiny, limit-order test only after a cash milestone. Maximum illustrative capital: the lower of S$100 or 1% of investible savings; brokerage and FX must be included. Expected result: learn whether the order converts, not guaranteed profit. Stop on delayed onboarding, customer dispute, working-capital strain or margin dilution. [I1][I2]

Sources and four-clock provenance

• I1 — original issuer filing: https://nsearchives.nseindia.com/corporate/SRIT_14112026085504_Intimation_of_Award_of_Contract_Final_Signed.pdf . Event: order received before issuer letter dated 2026-11-13; exact receipt time unavailable. NSE publication reported by the source PDF: 2026-11-14T08:56:53+05:30 = 2026-11-14T11:26:53+08:00. This is not established as the first public disclosure: a BSE filing index reports 14 November 08:41 IST. The issuer-hosted copy, https://www.sritindia.com/s/Intimation_of_Award_of_Contract_Final_Signed.pdf , was independently read for this publication. Its digital signature is dated 14 November 08:17:16 IST; signing is not publication. The original order-receipt time remains unknown. Source PDF's recorded retrieval: 2026-11-15T08:03:59+08:00. Cutoff: 2026-11-15T08:00:00+08:00. Geography/language: India/Qatar, English. The reported 14 November exchange-disclosure times fall inside the edition's preceding-24-hour window; exact first-publication time remains unverified. Underlying receipt time unavailable. Confidence: high on disclosed order, low on profit/cash.

• I2 — official NSE quote/announcement page: https://www.nseindia.in/get-quote/equity/SRIT/SRIT-India-Limited . Event/measurement: 2026-11-13T16:00:00+05:30 market reference. Page update: exact page-update timestamp unavailable. Source PDF's recorded retrieval: 2026-11-15T08:03:59+08:00. Cutoff: 2026-11-15T08:00:00+08:00. Historical/carried forward, not fresh price evidence.

• I3 — price-page contradiction: https://www.ndtvprofit.com/stocks/srit-india-share-price-SRIT and https://choiceindia.com/stocks/srit-india-ltd-share-price . Publishing recheck: NDTV shows ₹126.38, updated 13 November 2026 15:30, with a two-minute data-delay notice; Choice shows ₹116.04, updated 3 November 2026 15:51 IST. Different dates and source snapshots; not a comparable 14 November price pair. Source PDF's recorded retrieval: 2026-11-15T08:03:59+08:00. Cutoff: 2026-11-15T08:00:00+08:00. UNVERIFIED/INCOMPLETE for an executable quote.

Second to fifth consequence effect

2. Forecast by Q1 2027: if onboarding starts before matching customer payments arrive, SRIT may need to fund staff and deployment in the meantime. Payment terms are not disclosed, so customer prepayment could change that sequence. [I1] 3. Forecast by Q2 2027: accepted invoices would add billing evidence beyond the order announcement. Recognised revenue requires separate reporting and the applicable accounting conditions; an accepted invoice alone does not establish revenue or collected cash. [I1] 4. Forecast by Q3 2027: successful national deployment may create reference value with other health systems, but no second buyer is verified. [I1] 5. Forecast by Q4 2027: repeat work could lift service revenue; disproof is delayed onboarding, rejected invoices or weak margin. [I1]

The 20 intelligence layers

1. Money moving: QAR50m order disclosed; payment not shown. [I1] 2. Early purchasing: named Ooredoo order; deposit and first invoice unavailable. [I1] 3. Bottleneck: two- and three-year rollout, hospital/pharmacy onboarding and working capital; capacity data missing. [I1] 4. Hidden beneficiaries: integration staff, local support and network vendors may benefit; no subcontract is disclosed. [I1] 5. Company finances: order size known; segment sales, margin, cash, debt and customer concentration were not retrieved from a fresh original filing in this desk pass. INCOMPLETE. [I1] 6. Unit economics: not calculable without margin, milestone and staffing data. A S$100 investor test is illustrative, not observed economics. [I1] 7. Ownership activity: no fresh insider, institution, buyback or raise verified. INCOMPLETE. 8. Hiring: no fresh project hiring verified. INCOMPLETE. 9. Government pipeline: health/drug-control scope is named, but no separate government budget was retrieved. [I1] 10. Foreign-language warning: no Arabic original was retrieved. INCOMPLETE. 11. Behaviour before sales: a named buyer ordered; end-user uptake is unknown. [I1] 12. Contradiction: order is specific, but price snapshots have different dates and profit is not disclosed. [I1][I3] 13. Missing expected activity: no deposit, invoice, acceptance or cash milestone. Baseline: issuer order filing. [I1] 14. Commercialisation: managed-service order is commercial; delivery acceptance is pending. [I1] 15. Competitive weakness: rival performance and lost bids were not verified. INCOMPLETE. 16. Geography: Indian listed supplier, Qatari buyer, Singapore investor adds INR/SGD risk. [I1] 17. Historical OTR lesson: revision 41 says an order is not cash; applied directly. The source desk marked novelty checking incomplete. Publishing recheck reviewed all 202 published titles and searched SRIT, Ooredoo, Qatar and health-system; no matching underlying contract was found. This does not claim worldwide novelty. 18. Awareness/pricing: differently dated, non-executable source snapshots cannot establish underpricing. [I2][I3] 19. Disproof: no onboarding, invoice rejection, cash strain or margin dilution. 20. Immediate trigger: first accepted invoice and cash collection; deadline next two reported quarters; capital S$0 research or ≤S$100 after confirmation.

Publication verification notes

15 November 2026, 08:37 SGT: transferred from the 08:00 SGT research PDF, Investments candidate 1, preserving its article headings, order and substantive qualifications. Internal desk verdict and batch audit are not part of this public article. Narrow corrections: the original ₹126.10–₹127.75 quote comparison is not verified and is replaced by explicitly dated source snapshots; the NSE disclosure is not called the first publication; staff funding before collection is conditional on payment terms; accepted invoices are not automatically recognised revenue. The original research file and correction record are retained. The original issuer filing was checked independently. No customer payment, profit, subcontract, new-market entry or investment return is claimed. The illustrative capital limit is not personalised financial advice or evidence that a trade is suitable. The zero-cash tracking route does not require buying shares.

Report this passage